CAS Name: androst-4-en-3-one, 17-[(1-oxoheptyl)-oxy]-, (17β)-
Testosterone Suspension injection USP, provides Testosterone Suspension, a derivative of the primary endogenous androgen testosterone, for intramuscular administration. In their active form, androgens have a 17-beta-hydroxy group. Esterification of the 17-beta-hydroxy group increases the duration of action of testosterone; hydrolysis to free testosterone occurs in vivo. Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus Testosterone Suspension can be given at intervals of two to four weeks.
Testosterone Suspension used in males to treat primary hypogonadism (congenital or acquired) – testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. In females: metastatic mammary cancer. Other methods of counteracting estrogen activity in cases of adrenalectomy, hypophysectomy, and/or antiestrogen therapy.
|each ml contains:|
|Testosterone Suspension||USP||50 mg|
|Benzyl Alcohol||BP||0.9% v/v|
|Carmellose Sodium||BP||0.1% w/v|
|Water for Injections||BP||q.s.|
Packing: 10 * 1 miL Glass Vial
Dosage and administration
Effective adult dose (men): 100-700mg per week by intramuscular injection
During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).
Androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant